<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184884</url>
  </required_header>
  <id_info>
    <org_study_id>4-2014-0172</org_study_id>
    <nct_id>NCT02184884</nct_id>
  </id_info>
  <brief_title>Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The whole blood Thrombelastograph (TEG®) Platelet Mapping™ assay measures clot strength,
      maximal amplitude (MA), reflecting maximal platelet function, and detects the reduction in
      platelet function, presented as percentage inhibition, by both aspirin and clopidogrel. A
      study reported that the TEG® can be used as routine monitoring of the variability in ADP
      receptor inhibition and of antiplatelet therapy. Therefore, using TEG Platelet Mapping assay,
      we could find out the perioperative clopidogrel responsiveness of the patients with ACS
      undergoing OPCAB.

      The purpose of this study is to determine whether the rate of the major adverse cardiac
      events (MACE, a combined endpoint of MI, revascularization and cardiac death) is higher in
      the patients with high degree of clopidogrel resistance, who are scheduled to undergo the
      OPCAB due to ACS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">March 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of the major adverse cardiac events</measure>
    <time_frame>at 30 days after surgery</time_frame>
    <description>major adverse cardiac events(MACE) includes the MI, revascularization and cardiac death. Rate of the MACE will be higher in the patients with high degree of clopidogrel resistance.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">195</enrollment>
  <condition>Acute Coronary Syndrome (ACS)</condition>
  <arm_group>
    <arm_group_label>MACE group</arm_group_label>
    <description>the patients with MACE after OPCAB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no MACE group</arm_group_label>
    <description>the patients without MACE after OPCAB</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MACE after OPCAB</intervention_name>
    <arm_group_label>MACE group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>without MACE after OPCAB</intervention_name>
    <arm_group_label>no MACE group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with acute coronary syndrome (ACS) undergoing off-pump coronary artery bypass
        surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. the patients with ACS undergoing OPCAB

          2. the patients over 20 years of age

          3. the patient who have been taking [100 mg of Aspirin] and [75 mg of clopidogrel or 180
             mg of ticagrelor] for more than one week and who continue within 3 to 5 days prior to
             surgery

        Exclusion Criteria:

          1. re-operation or emergency operation

          2. the patients with bleeding tendency of decreased liver function

          3. Left ventricular ejection fraction &lt; 40% by echo

          4. preoperative hematocrit &lt; 33% or platelet count &lt; 100,000/mm3 or creatinine &gt; 1.4
             mg/dL

          5. abnormal preoperative prothrombin time or activated partial thromboplastin time

          6. preoperative use of other PO antiplatelet drugs or PO anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>off-pump coronary artery bypass surgery, clopidogrel responsiveness, ischemic outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

